Asia-pacific Alzheimer’s Disease Therapeutics & Diagnostics Market Forecast 2022-2030

Asia-pacific Alzheimer’s Disease Therapeutics & Diagnostics Market Forecast 2022-2030


The Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market is set to progress with a 6.89% CAGR across the forecasting period of 2022 to 2030. The rising prevalence of dementia and rapidly growing population in developing countries are driving the market growth.


The Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market growth estimation covers the analysis of South Korea, Thailand, Indonesia, China, India, Vietnam, Australia & New Zealand, Japan, and Rest of Asia-Pacific. The Indian healthcare system is experiencing immense progress due to the growing economy. The demand for new healthcare technological advancements in the treatment and early diagnosis of dementia and cognitive impairment is rising due to the increasing burden of Alzheimer’s disease throughout the country.

Furthermore, the entire population of South Korea is rapidly aging. According to the World Population Ageing 2019 report, the population aged above 65 years or above is expected to reach 12.658 million by 2030, which was 7.715 million in 2019. The surging geriatric population is prone to neurological disorders like Alzheimer’s disease and other dementias, which is expected to drive the market over the forecast period.

Additionally, according to Alzheimer’s Disease International, in 2015, Alzheimer’s Indonesia launched a project called Dementia Friendly Jakarta with the governor’s support. In 2012, there were nearly 21 million older people, and the projected number of patients suffering from Alzheimer’s is expected to reach about 5,18,000 by 2024, supplementing the growth of the Indonesia Alzheimer’s disease therapeutics & diagnostics market.


Prominent companies operating in the market include Sun Pharmaceuticals Industries Ltd, GE Healthcare, Lupin Limited, Novartis AG, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
3. Market Dynamics
3.1. Parent Market Analysis
3.2. Key Drivers
3.2.1. Growing Geriatric Population
3.2.2. Rising Pervasiveness Of Alzheimer’s Disease
3.2.3. Emerging Novel Diagnostic Technologies
3.2.4. Increasing Pipeline Drugs
3.3. Key Restraints
3.3.1. Failure Of The Late-stage Drugs
3.3.2. Stringent Government Regulations
3.3.3. Lack Of The Availability Of Surrogate Markers
4. Key Analytics
4.1. Timeline Of Alzheimer’s Disease Therapeutics & Diagnostics Market
4.2. Phases And Sternness Of Alzheimer’s Disease
4.3. Impact Of Covid-19 On Alzheimer’s Disease Therapeutics & Diagnostics Market
4.4. Key Market Trends
4.5. Porter’s Five Forces Analysis
4.5.1. Buyers Power
4.5.2. Suppliers Power
4.5.3. Substitution
4.5.4. New Entrants
4.5.5. Industry Rivalry
4.6. Key Buying Criteria
4.7. Supply Chain Analysis
4.8. Opportunity Matrix
4.9. Vendor Landscape
5. Market By Therapeutics & Diagnostics
5.1. Therapeutics
5.1.1. Drugs Marketed Drugs Pipeline Drugs
5.1.2. Disease Stage Late-stage: Severe Ad Early/Middle Stage: Mild To Moderate Ad Prodromal Stage
5.1.3. Generic & Branded Branded Generic
5.2. Diagnostics
5.2.1. Lumbar Puncture Test
5.2.2. Positron Emission Tomography
5.2.3. Electroencephalography
5.2.4. Magnetic Resonance Imaging
5.2.5. Computed Tomography
5.2.6. Blood Test
5.2.7. Other Diagnostics
6. Geographical Analysis
6.1. Asia-pacific
6.1.1. Market Size & Estimates
6.1.2. Key Growth Enablers
6.1.3. Key Challenges
6.1.4. Key Players
6.1.5. Country Analysis China Japan India South Korea Indonesia Thailand Vietnam Australia & New Zealand Rest Of Asia-pacific
7. Competitive Landscape
7.1. Key Strategic Developments
7.1.1. Mergers & Acquisitions
7.1.2. Product Launches & Developments
7.1.3. Partnerships & Agreements
7.1.4. Business Expansions, Announcements, & Divestitures
7.2. Company Profiles
7.2.1. Allergan Plc (Acquired By Abbvie)
7.2.2. Amarantus Bioscience Holdings Inc
7.2.3. Baxter International Inc
7.2.4. Biogen Inc
7.2.5. Cognoptix Inc
7.2.6. Eisai Co Ltd
7.2.7. Eli Lilly & Company
7.2.8. F Hoffmann-la Roche
7.2.9. Ge Healthcare
7.2.10. Johnson & Johnson
7.2.11. Lupin Limited
7.2.12. Merck & Co Inc
7.2.13. Novartis Ag
7.2.14. Pfizer Inc
7.2.15. Siemens Healthineers Ag
7.2.16. Sun Pharmaceuticals Industries Ltd
7.2.17. Teva Pharmaceutical Industries Limited
7.2.18. Zydus Cadila

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook